BACKGROUND Within the SCOT-HEART (Scottish COmputed Tomography of the HEART Trial) trial of patients with stable chest pain, the use of coronary computed tomography angiography (CTA) reduced the rate of death from coronary heart disease or nonfatal myocardial infarction (primary endpoint).
C oronary computed tomography angiography (CTA) has high sensitivity and specificity for the detection of coronary artery disease (1, 2) . This has prompted the evaluation of coronary CTA as a diagnostic test for coronary artery disease in patients presenting with stable chest pain. The short-term benefits of coronary CTA in this population have included better diagnostic certainty, lower rates of normal coronary arteries at the time of invasive coronary angiography, and improved targeting of symptomatic and preventative therapies (3, 4) .
Large-scale clinical trials have also suggested that short-term coronary heart disease events are reduced (4, 5) . In the SCOT-HEART (Scottish COmputed Tomography of the HEART Trial), we recently reported the effects of coronary CTA on the pre-specified 5-
year clinical outcomes including investigations, treatments, and clinical events (6). We demonstrated that an initial strategy of coronary CTA was associated with a 41% relative risk reduction in coronary heart disease death or nonfatal myocardial infarction at 5 years. This major reduction in events has prompted questions about the mechanisms of benefit, the potential for bias, and the plausibility of the effect size.
We here present further analyses of the 5-year data from the SCOT-HEART trial to assess the robustness of the event reductions seen with coronary CTA with respect to the participant subgroups, the changes in diagnosis, and the alterations to procedural and pharmacological treatments. Drawing these disparate effects together, we wanted to determine the overall attribution of benefits in relation to the primary endpoint and the study intervention effect size.
METHODS
The study population and trial design were reported previously (4, 5, 7) . In brief, adult patients age #75 years who attended the outpatient cardiology clinic with stable chest pain were invited to participate in the trial in 12 cardiology centers across Scotland between 2010 and 2014. They were randomized 1:1 to standard care alone or standard care plus coronary CTA. (11) . This has been successfully applied in other settings (12, 13) and for longer-term clinical trial followup (14) . The full set of assumptions are given in the Online
Appendix. However, we wish to highlight that we modeled a scenario wherein the highest risk (most appropriate) patients were those who had received additional preventative therapies as a result of the coronary CTA intervention given that this would be the consequence of improved diagnostic precision.
Under the observed difference between the trial arms in use of preventative therapies, this represents a best-case scenario.
Statistical significance was taken as a 2-sided p < 0.05. All analysis was undertaken using R version 3.5.0 (R Foundation, Vienna, Austria).
RESULTS
We randomized 4,146 patients with stable chest pain at 12 cardiology centers across Scotland to either standard of care alone (n ¼ 2,073) or standard of care Values are n (%) or mean AE SD.
CHD ¼ coronary heart disease; CTA ¼ computed tomography angiography. Adamson et al. Among patients referred for invasive coronary angiography, those randomized to CTA had more extensive burden of coronary artery disease Five-year incidence rates of CHD death or nonfatal MI in patients with (right) and without (left) a diagnosis of angina due to CHD 6 weeks after randomization according to the trial allocation of standard care alone (red) and computed tomography coronary angiography plus standard of care (blue). Figure 1 .
Abbreviations as in
Adamson et al. Under the counterfactual scenario where the proportion of participants receiving preventative therapy was the same in both arms, the estimated number of events in the coronary CTA group was 84.4 (i.e., similar to that observed in the control arm).
DISCUSSION
We report a post hoc analysis of the long-term follow- One of the main advantages of coronary CTA is its negative predictive value. As such, it moves beyond traditional symptom assessment and ischemia testing, providing confidence to clinicians and patients alike regarding the absence of disease. This was Values are n (%). *Denominator excludes those receiving therapy at baseline. †Prognostically important CAD defined as any of the following: $50% stenosis of left main coronary artery; $70% stenosis of at least 3 main epicardial arteries; or $70% stenosis of at least 2 epicardial arteries including the proximal left anterior descending artery. Tables 1 and 3 . Landmark analysis demonstration cumulative incidence curves for coronary revascularization within the first year and beyond 1 year in patients allocated to standard care alone (red) and computed tomography coronary angiography (CTCA) plus standard of care (blue).
Abbreviations as in
Adamson et al. 
Findings on Coronary CT Angiography
Normal Non-Obstructive Obstructive disease was a key factor associated with de novo provision of evidence-based preventative therapies among those who underwent coronary CTA.
Coronary revascularization was more common in the coronary CTA group during the first year after randomization. We here show this reflects increased early detection of obstructive coronary artery disease that includes left main stem and triple vessel disease.
Coronary revascularization may be particularly impactful in those with prognostic disease and those with new onset, rapidly progressing, or recurrent angina, in whom underlying atherosclerotic disease process may be more active. This is potentially important as coronary revascularization is known to reduce ischemic coronary events and improve clinical outcomes in these more unstable clinical contexts (20, 21) . In contrast, beyond 1 year, rates of coronary revascularization were higher in those who had received standard care alone and many of these is important and many patients in the standard care group may be receiving futile treatments because many will not have underlying coronary disease. For the first time, we here report that those undergoing coronary CTA will have more directed and appropriate therapies. Indeed, when we look at those who underwent coronary CTA, the rates of antiplatelet and statin therapy use were almost 3-fold higher in those with coronary artery disease compared with those without disease despite identical 10-year cardiovascular risk scores. Thus, simply looking at the overall frequency of prescribing of preventative therapies ignores the importance of how such medications are distributed within a population. Again, these findings suggest that coronary CTA is consistent with a precision medicine approach by identifying the most appropriate treatment for each patient.
Using treatment effect estimates from published randomized controlled trials, systematic reviews, and meta-analyses (14, 16, (21) (22) (23) (24) (25) (26) , we explored for the first time whether the effect of additional treatment with antiplatelet, statin, and revascularization interventions could account for the observed effect size. Whereas this modeling required a number of assumptions, they were nonetheless reasonable, and more reasonable than assuming that patients receiving additional treatment in the coronary CTA group shared the same cardiovascular event rate as the entire cohort. This modeling allowed us to demonstrate that at least some of the effect size we observed was plausible and could be accounted for by current evidence. In addition, we would also highlight that the effect size reported in the SCOT-HEART trial is consistent with rates of myocardial infarction reported in other trials of coronary CTA in patients with stable chest pain (5,27) and meta-analyses (28, 29) , as well as large-scale observation studies (30) . Moreover, our model neither accounts for positive lifestyle changes, such as smoking cessation, nor treatment compliance, which may also have a beneficial impact given the greater uptake of antiplatelet and statin therapy in those diagnosed with coronary artery disease by coronary CTA. We accept that many of our modeling choices are necessarily subjective, and we are pleased to provide access to the data to allow other researchers to test the effect of different assumptions. Finally, we would highlight that the magnitude of the effect size we described in the SCOT-HEART trial is consistent with other diagnostic studies in patients with suspected coronary heart disease (14) , as well as primary prevention trials in However, we think this is unlikely. First, the delayed separation of the event curves suggests that there was no early bias in event reporting because the CT result would be available after 2 weeks, whereas treatment changes took a further 4 to 6 weeks to implement.
Second, the finding that coronary CTA was associated with less normal invasive coronary angiography and higher early rates of revascularization suggests that the coronary CTA more accurately identified the disease process. Third, coronary CTA increased the rate A recent Cochrane Systematic Review (32) has also reported similar trial outcomes irrespective of central versus local endpoint determination. Ultimately, for a pragmatic trial determining the effect of introducing a new diagnostic test into a health care system, the main goal is to establish the impact on health care outcomes as reported by that health care system. We believe clinical outcomes reported by routine health records data remain the most appropriate, independent, and accurate method of clinical endpoint ascertainment for the SCOT-HEART trial. Finally, we acknowledge our modeling approach does assume that the highest risk patients were those who had received additional preventative therapies as a result of the coronary CTA intervention, and this may have overestimated some of the benefits. This is particularly applicable to the assumption of treatment benefit derived from coronary revascularization.
Although we chose treatment effects applicable to an unstable angina population, we believe this is justifiable as the shape of the instantaneous hazard curves supports a high short-term risk that plateaus after 6 to 12 months in a pattern consistent with acute coronary syndrome populations.
CONCLUSIONS
We have presented a multifaceted analysis that consistently and robustly demonstrates the plausibility of a reduction in long-term coronary events consequent on investigating patients with stable chest pain using coronary CTA. If we are to improve the prevention of future myocardial infarction, coronary CTA would appear to be the most effective and indeed the only proven investigative approach in patients with stable chest pain. 
